期刊名称：JOURNAL OF CLINICAL LIPIDOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
 The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal's readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians.
Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
Instructions to Authors
Official Journal of the National Lipid Association
Journal of Clinical Lipidology is the Official Journal of the National Lipid Association.
STATEMENT OF PURPOSE
The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism.
Journal of Clinical Lipidology provides rapid online electronic and print publication of the most important current scientific developments in the field of lipids and lipidology. The Journal publishes both clinical and basic original, peer-reviewed articles devoted to diagnosis and treatment lipid disorders. Sections of the Journal address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
In general, review articles are invited, and unsolicited submissions will be considered. All articles are sent for peer-review.
COPYRIGHT ASSIGNMENT
Authors are required to assign the copyright to the National Lipid Association through publisher's copyright transfer form prior to publication.
GENERAL
Authors of manuscripts submitted to Journal of Clinical Lipidology will receive a timely review and will be notified within two months as to whether their work is accepted, rejected, or requires revision. Manuscripts should be prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, available at:  http://www.icmje.org.
PREVIOUS PUBLICATION OR DUPLICATE SUBMISSION:
Manuscripts are considered with the understanding that they have not been published previously in print or electronic format and are not under consideration by another publication or electronic medium. Copies of possibly duplicative materials (ie, those containing substantially similar content or using the same or similar data) that have been previously published or are being considered elsewhere must be provided at the time of manuscript submission.
PREVIOUS PRESENTATION OR RELEASE OF INFORMATION:
A complete report following presentation at a meeting or publication of preliminary findings elsewhere (e.g. an abstract) can be considered. Media coverage of meeting presentations will not jeopardize consideration, but direct release of information through press releases or news media briefings may preclude consideration by the journal.
AUTHORSHIP:
Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. One or more authors should take responsibility for the integrity of the work as a whole, from inception to publication. Authorship credit should be based on (1) substantial contributions to conception and design; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. All conditions must be met. Authors are required to identify their contributions to the work described in the manuscript.
CONFLICT OF INTEREST:
All authors must disclose any conflict of interest they may have with an institution or product that is mentioned in the manuscript and/or is important to the outcome of the study presented. This would include funding for the research, membership in any speaker's bureau or corporate advisory committee, stockholder, or support for travel. Authors should also disclose conflict of interest with products that compete with those mentioned in their manuscript. The Editor will discuss with the authors on an individual basis the method by which any conflicts of interest will be communicated to readers. Manuscripts without conflicts of interest disclosure from all authors will be returned.
MANUSCRIPT and FIGURE PREPARATION (See manuscript format and categories for further details)
Manuscripts must be submitted via the Elsevier Editorial System (EES) website for this journal; go to http://ees.elsevier.com/jclinlipid/ and select "Submit Manuscript". You will be guided stepwise through the creation and uploading of the various files and data. Once the uploading is done, the system automatically generates an electronic (PDF) proof, which is then used for reviewing. All correspondence regarding submitted manuscripts will be handled via e-mail through EES.
For text files, Microsoft Word is preferred, although any editable text file is acceptable (e.g., .doc, .txt, .rtf). Do not embed artwork with text. Separate files for each figure are required. TIF or EPS figure files are strongly preferred, at the standard resolutions (i.e. 300 dpi for photos, 1200 dpi for line art) and scaled to size. Other figure formats may be supported provided artwork guidelines on http://ees.elsevier.com/jclinlipid/ are strictly followed. PDF files cannot be used for typesetting purposes for either text or figures. Arrange the contents in the following order:
1. Cover letter;
2 Title page (Include degrees for all authors and corresponding author contact information, and all conflicts of interest);
3. Abstract (Required for original and review articles);
4. Key words (5-10);
5. List of abbreviations used in the manuscript (Use ONLY those that are commonly accepted.);
6. Text (Double-spaced, single columned with a minimum of 1-inch margins on all four edges;
7. References (Cite all authors);
8. Tables;
9. Figure legends;
10. Figures (save each as a separate file for upload, Figures (save each as a separate file for upload, or compress all into one ZIP file for upload; the system will "unpack" a .zip file automatically and allow you to properly identify each figure file. Go to www.winzip.com for a free trial of this compression software.)
MULTIMEDIA COMPONENTS
Images
Submissions to "Multimedia Library: Images and Videos" are limited to 1, double-spaced typewritten narrative (495 words for a 1 column figure; 425 words for a 1½ column figure), and no more than 2 illustration panels and 4 authors. Figure legends should not be used, but up to 5 reference citations are permitted. Images are judged according to their aesthetic quality, the importance and effectiveness of their scientific or clinical message, or their utility as a teaching tool. Unlike case reports, the focus should be on the image, not the narrative.
Authors can also include a single electronic movie (e.g. Quicktime or MPEG1 formats) file or computer animation (e.g. as Power Point file) that expands or enhances the message of the printed images. Submissions need not necessarily convey entirely novel findings so long as the animations or movies are judged to provide novel or especially useful means of conveying known principles (e.g. Animations or movies that effectively teach/portray an electrophysiological mechanism or process). If an electronic movie or animation is submitted, the authors must also provide 1 or 2 frames of images (which will appear in print) that convey the essence of the movie's content. Published images, movies, and animations will be made available via the Journal's web site to subscribers to the Journal of Clinical Lipidology.
MANUSCRIPT FORMAT
Cover letter:
Manuscripts submitted must be original, with no portion under simultaneous consideration for publication elsewhere or previously published, except for an abstract of fewer than 400 words. Studies involving experimental animals and humans must conform to the guiding principles of the Declaration of Helsinki, and human subjects must have given informed consent of a study that has been approved by the Institutional Committee on Human Research at the authors' institution. Any financial or other relations must be disclosed. Cover letters must include affirmation of the above.
Title Page:
Please include a brief and descriptive title of the article, a short title of fewer than 50 characters, authors full names, academic degrees, hospital and academic affiliations, acknowledgment of ALL sources of financial support, potential conflicts of interests for all authors, and the name, address, phone and fax numbers, and E-mail of the individual responsible for editorial correspondence and/or reprint requests. Please upload title page separately from the manuscript.
Abstract (page 1): Please include a brief abstract (without references) of fewer than 250 words for Original Articles. Divide the abstract into sections: Background, Objective, Methods, Results, and Conclusion that states the importance and potential implications of the observations. Following the abstract, list 5 to 10 key words suitable for indexing.
For Reviews and Case Studies, please follow the format instructions below:
Reviews: (250 words) Background (justify relevance to readership), Sources of material, abstract of findings and conclusion.
Case Studies: Brief of overview of the problem and major management decisions required o resolve the case.
Glossary of abbreviations used in the manuscript: Avoid ALL abbreviations other than standard units of measurement and common abbreviations, such as RV, LV, etc.
Text:
Begin the text on page 3 and organize into sections: Introduction, Methods, Results, Discussion, and Conclusion, with appropriate subheadings to make the sections easily understood. Explain abbreviations at first mention, followed by the abbreviation in parentheses. References, tables, and figures should be cited in numerical order. Avoid jargon, cliches, and laboratory slang. References to medical devices, equipment and drugs must adhere to code structures and usage conventions set forth by NLA code. Place acknowledgments at the end of the text, before references. The manuscript should not exceed 20 double-spaced typed pages, 8 figures, 3 tables, and 35 references. Authors whose native language is not English are STRONGLY advised to seek appropriate grammatical assistance. Poorly written manuscripts are at a disadvantage. Do not include any author contact information within the text.
References:
Number references in numerical order in the text. Include references to unpublished material or personal communications in the text in parentheses. Abbreviate titles of periodicals according to the style of Index Medicus, National Library of Medicine. List all authors in each reference following exactly the format and punctuation shown below.
Journal Article-Example
Huikuri HV, Tapanainen JM, Lindgren K, Raatikainen P, Makikallio TH, Juhani Airaksinen KE, Myerburg RJ: Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol. 2003;42:652-8.
Chapter in Book with Different Author and Editor-Example
La Rovere MT, Schwartz PJ. Baroreflex sensitivity. In: Opie L, ed. Drugs for the Heart. 6th ed. Philadelphia: WB Saunders; 2006:67-93.
Please note that the Journal of Clinical Lipidology's reference style is now included in the EndNote® bibliographic system. Authors are responsible for the accuracy and completeness of their references and for correct text citation.
Tables:
Tables must be self-explanatory and supplement, not duplicate, the text. Number brief titles in Arabic numerals according to the order of mention in the text. Each table should be typed on a separate page and designed for economy of space and readability. Do not imbed tables within the text. Notes designated in the tables and all abbreviations should be defined in a footnote. Abbreviations should be identified in alphabetical order. Footnotes should be used in the following order: *,†, ‡, §, ||, ¶, #
Figure Legends/Figures:
(See detailed figure requirements under manuscript and figure preparation).
Manuscripts with incorrect format or that are over maximum length will be returned unreviewed
Permissions:
Authors must submit written permission upon manuscript submission from both the author and publisher of the original source when material is reproduced from other sources. This permission must include reproduction in both print and electronic formats for worldwide distribution.
Acknowledgements:
Acknowledgement(s) require written permission of the person being acknowledged.
Proofs:
To avoid publication delay, authors must return proofs in 48 hours.
Responsibility:
Manuscripts are subject to editorial modification to bring them into conformity with the style of the journal. Statements in articles or opinions expressed by any contributor in any article, including changes made by the copy editor and approved by the corresponding author, are not the responsibility of the editors or the publishers.
Manuscript Categories:
Original Contribution
Case Studies. Case studies are limited to 4 authors, 8 double-spaced pages total, including text, references (<20), figure legends, and 4 figures. No abstract included.
Reviews. Contemporary and Historical Reviews (Solicited and Unsolicited)
Review articles should contain a brief abstract and be 5000 total words, including references, tables, and figures. References are 30 and must be 5 years old. Use other articles to incorporate older references.
Letters to the Editor. Letters should be double-spaced, not exceeding 450words. Letters will be reviewed and are subject to editing. They should not contain original data or figures. If accepted for publication, a copy of the letter will be sent to the author(s) of the original article, if applicable. The author(s) will have an opportunity to respond with new material that will be considered for publication with the letter.
Editorial Commentary. All articles by invitation only
Commentaries should be confined to articles in the current issue or a very specific topic that is current and high interest to the readership.
News from the NLA.
Critique of Recent Publications: This should be a commentary on recent publications that are of very high interest to the readership such as large trials of lipid altering drugs, new laboratory methods, and new genetic linkage studies of lipid disorders. The author should be invited based on intimate knowledge of the area of study and an understanding of the implications of the clinical impact. The Critique should give: title, reference, study question, major methods, results, conclusion of the authors, and an opinion statement as to the impact this will have on our thought process and/or our actions in the clinical arena. This should be limited to approximately 5 publications within the previous 6 months. The 5 publications/articles to be critiqued should be construed as essential material that all clinical lipidologists should know in some detail. The abstracts for these areas should be organized like those for the Review Articles. Examples of topics to be addressed include:
New Pharmacology.
Provide a discussion of new drugs in development or new important discoveries regarding drugs that are already available. Please emphasize those drugs that are nearing completion of Phase 3 in the FDA approval process.
New from the Laboratory.
Short articles (up to 2 typeset pages) on laboratory developments (of great interest and relevance to the clinician) focusing on the issues of clinical utility, accuracy, positive predictive value etc. (an example for this section: should we be using apolipoprotein measures, inflammatory markers, diagnostic indicators for sub-clinical vascular disease, etc.)
Patient Education and Lifestyle.
This area brings in many of the issues for the dietitian and nurse educator. New OTC agents, dietary issues, drug compliance, exercise benefits.
Updated April 2009
Editorial Board
Editor-in-Chief:
W. Virgil Brown, MD
Emory University School of Medicine, Atlanta, GA
Managing Editor:
Angelica Kerr
Elsevier, New York, NY
Associate Editors:
Christie M. Ballantyne MD
Cardiovascular Disease Prevention, Vascular Medicine, Methodist DeBakey Heart and Vascular Center and Baylor College of Medicine, Houston, TX
Thomas P. Bersot MD
Lipidology, Arteriosclerosis, Thrombosis, and Vascular Biology, University of California, San Francisco San Francisco, CA
Vera Bittner MD, MSPH
Cardiovascular Disease, Preventive Cardiology, Lipidology, University of Alabama, Birmingham, AL
Alan Chait MD
Endocrinology, Nutrition and Metabolism, University of Washington, Seattle, WA
Michael H. Davidson MD
Preventive Cardiology and Atherosclerosis, Pharmacology, Radiant Research, Chicago, IL
Jean Davignon MD, MSc
Lipidology, Clinical Research Institute of Montreal, Montreal,Quebec, Canada
Ira Goldberg MD
Basic Lipid Physiology, Columbia University Medicine, New York, NY
Ronald B. Goldberg MD
Diabetes, University of Miami School of Medicine, Miami, FL
John R. Guyton MD
Clinical Management, Duke University Medical Center, Durham, NC
Terry A. Jacobson MD
Epidemiology, Disease Prevention, Clinical Trials, Terry A. Jacobson, MD FACP FAHA, Emory University School of Medicine, Atlanta, GA
Peter H. Jones MD
Lipidology, Atheroclerosis, Baylor College of Medicine, Houston, TX
Penny Kris-Etherton PhD, RD
Nutrition, Dietetics, Penn State University, University Park, PA
Edgar V. Lerma MD
Diabetes, Lipidology, and Nephrology, University of Illinois at Chicago, College of Medicine/Associates in Nephrology, S.C., Chicago, IL
Maria Lopes-Virella MD, PhD
Diabetes, Immunology, Medical University of South Carolina, Charleston, SC
James M. McKenney PharmD
Pharmacology, Clinical Trials, National Clinical Research, Inc., Richmond, VA
Daniel J. Rader MD
Preventive Cardiovascular Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA
Jennifer G. Robinson MD, MPH
Cardiovascular Disease Epidemiology, University of Iowa, Iowa City, IA
Frank M. Sacks MD
Lipidology, Nutrition, Harvard School of Public Health, Boston, MA
Allan D. Sniderman MD FRCP(C) FRSC
Cardiology, Lipidology, McGill University Health Centre, Montreal, QC, Canada
Evan Stein MD, PhD
Laboratory Analysis, Pediatric Lipidology, Clinical Lipidology, Metabolic & Atherosclerosis Research Center, Cincinnati. OH
Neil J. Stone MD
Pathology, Cardiology, Lipidology, Clinical Cardiology and Clinical Lipidology, Winnetka, IL.
Don P. Wilson MD
Pediatric Lipid Management, Texas A&M Health Science Center College of Medicine, Phoenix, AZ
Peter W. Wilson MD
Lipid Management, Phoenix Children's Hospital, Phoenix, AZ
Editorial Board:
Nicola Abate MD
Dallas, TX
Eyad Alhaj MD
Florence, KY
Mouaz H. Al-Mallah MD
Detroit, MI
Billy S. Arant, Jr., MD
Chattanooga, TN
Kimberly Birtcher MS, PharmD, BCPS, CDE
Houston, TX
Michael Bottorff PharmD
Cincinnati, OH
Lynne T. Braun RN, APN
Chicago, IL
Eliot A. Brinton MD
Salt Lake City, UT
David Capuzzi MD, PhD
Wynnewood, PA
Alan Chait MD
Seattle, WA
Elena Citkowitz MD, PhD, FACP
New Haven, CT
John H. Contois PhD
Portland, ME
Marshall Ayer Corson MD
Seattle, WA
Stephen R. Crespin MD
St. Louis, MO
William C. Cromwell MD
Raleigh, NC
Robin Crouse MD
Winston-Salem, NC
Thomas Darice Dayspring MD, FACP
Wayne, NJ
Dave L. Dixon PharmD
Winston-Salem, NC
Carlos A. Dujovne MD
Mission, KS
Daniel Duprez MD, PhD, FACC, FAHA, FESC
Minneapolis, MN
James Falko MD
Denver, CO
Sergio Fazio MD, PhD
Nashville, TN
Gerald Fletcher MD
Jacksonville, FL
Jeffrey S. Freeman DO, FACOI
Philadelphia, PA
Stephen A. Geraci MD, FACC, FDP, FAHA, FACP
Jackson, MS
Edward A. Gill MD
Seattle, WA
Douglas Hammer MD, MPH, DrPH
Raleigh, NC
Charles R. Harper MD
Atlanta, GA
Linda C. Hemphill MD
Boston, MA
D. Roger Illingworth MD
Portland, OR
Matthew Ito PharmD, FCCP, BCPS
Portland, OR
Jack J. Kleid MD, FACC, FACP, FAHA
San Diego, CA
Bruce A. Kottke MD, PhD
Lakeland, FL
Sandra Kreul ARNP, MSN
Valrico, FL
Kevin C. Maki PhD
Glen Ellyn, IL
Carol M. Mason ARNP
Trinity, FL
Catherine J. McNeal MD, PhD
Temple, TX
David G. Meyers MD, MPH, FACC, FAHA, FACPM
Kansas City, KS
Michael Miller MD, FACC, FAHA
Baltimore, MD
Anne N. Nafziger MD, MHSASKS
Albany, NY
Stephen Nash MD, FACC, FAHA
Syracuse, NY
Shailesh B. Patel BM, ChB, PPhil, FRCP
Milwaukee, WI
Gregory S. Pokrywka MD
Towson, MD
Michael Prisant MD, FACC, FAHA
Augusta, GA
Vasudevan Raghavan MBBS, MD, MRCP(UK)
Columbus, OH
Michael F. Richman MD
Santa Monica, CA
Giacomo Ruotolo MD, PhD
Milano, Italy
Edward Shahady MD
Fernandina Beach, FL
Mona Shimshi MD, FACE
Scardsdale, NY
Scott W. Shurmur MD
Omaha, NE
Donald A. Smith MD, MPH
New York, NY
James H. Stein MD
Madison, WI
Mary Ellen Sweeney MD
Atlanta, GA
Peter P. Toth MD, PhD, FAAFP, FICA, FAHA, FCCP, FACC
Sterling, IL
James A. Underberg MD
New York, NY
Ralph M. Vicari MD
Melbourne, FL
Yoel Vivas MD
Pittsburgh, PA
G. Russell Warnick, MS, MBA
Alameda, CA
Perry Jay Weinstock MD, FACC
Camden, NJ
Robert Allen Wild MD, PhD, MPH
Oklahoma City, OK
Don P. Wilson MD
Temple, TX
Michael J. Zema MD, FACP, FACC, FCCP, FCP, FASE, FASNC, FACA, FICA
Patchogue, NY
Paul Ziajka MD, PhD
Winter Park, FL
Issam Zineh PharmD
Gainvesville, FL
|
